Unfortunately we may have to wait till mid 2026 for approval.
Well, one comfort is that approval for Flaskworks + GBM n and r and I’m speculating here, but possibly also DCVax-L as part of a UK-wide regulatory framework for autologous dendritic-cell vaccines in a single PR would create far more fireworks than approval for manual-production DCVax-L for GBM n and r only.